ClinicalTrials.gg
Active, not recruitingNCT06137807TRICAV-IUpdated Aug 28, 2026

TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)

An interventional study of TricValve® Transcatheter Bicaval Valve System in Tricuspid Regurgitation and Tricuspid Valve Disease, sponsored by P+F Products + Features USA Inc.. Active, not recruiting at 36 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by P+F Products + Features USA Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 60 studies in Tricuspid Valve Insufficiency with a site in United States — 27 open to participants now, 36 under way, none of them phase 3. Tricuspid Valve Insufficiency · United States.

Planned enrollment
25th of 42
50 · median 63
Started
2024
with 7 others
No phase
39 of 60
18 open now
Primary completion
2026-09
later than 10 of 35 live
Registered
40th of 60
by date
Lead sponsor
2 of 60
P+F Products + Features USA Inc.

Among the 60 studies in Tricuspid Valve Insufficiency with a site in United States, this one is the 25th largest by planned enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2024, is one of 39 with no phase, reaches primary completion later than 10 of the 35 other live ones, and was the 40th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

27 of the 60 studies in Tricuspid Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Tricuspid Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcatheter Bicaval Valves are pre-mounted into the TricValve® Delivery System which is used for percutaneous access and delivery of the TricValve® Transcatheter Bicaval Valve in the vena cava. The system is a single use, sterile device compatible with all the valve sizes. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system.

Read the detailed description

This is a prospective multicenter clinical investigation designed to evaluate the safety and effectiveness of the TricValve® Transcatheter Bicaval Valve System for improving outcomes in symptomatic subjects with severe TR deemed by the local Heart Team to be at high risk for tricuspid valve surgery.

Patients who meet all of the study inclusion criteria, will be treated with the TricValve System. After the intervention, patients will be followed up closely for 12 months. Long term safety and efficacy data will be collected annually up to 5 years.

03

Conditions studied

  • Tricuspid Regurgitation
  • Tricuspid Valve Disease

Keywords

  • Tricuspid Regurgitation
  • Heart Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be 18 years or older, at the time of signing the .
  2. Subjects has severe tricuspid regurgitation (TR), as determined by the qualifying transthoracic echocardiogram (TTE) confirmed by an echocardiography Core Lab.
  3. Class III-IVa (not on inotropes, IABP or LVAD) or heart failure (HF) admission in the past 6 months.
  4. Subject is adequately treated with optimal medical therapy (OMT) for heart failure per the local Heart Team for at least 30 days prior to the index procedure, including a diuretic.
  5. The local Heart Team and IEC determine that the patient is eligible for the TricValve procedure.
  6. For females of , negative pregnancy test.
  7. Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Subject had a recent MI, stroke or cardiovascular accident; underwent coronary artery bypass graft surgery, had a percutaneous coronary intervention or other major cardiovascular surgery within 90 days prior to TricValve implantation.
  2. Subject requires another planned major cardiac procedure, including left-sided transcatheter intervention or surgery (e.g. severe aortic stenosis, severe mitral regurgitation), coronary artery bypass or PCI or pulmonary valve correction. Please note that if closure of an ASD, iatrogenic ASD or PFO is performed, TricValve implantation can be performed 30 days after the intervention. Additionally, TricValve implantation can be performed 30 days after any Electrophysiology procedure (pacemaker, ICD, etc.).
  3. ≤ 30% on echocardiography.
  4. Evidence of intracardiac, inferior vena cava (IVC), or femoral venous mass, thrombus or vegetation.
  5. Tricuspid stenosis. (Per TVARC, echo criteria: TVA at least 1.5 cm2 or TVAi at least 0.9 cm2/m2 [at least 0.75 if >30 kg/m2], DVI \<2.2, mean gradient \<5mm Hg); reduction of total tricuspid regurgitation to optimal (≤ mild [1+]) or acceptable (≤ moderate [2+]).
  6. Severe right ventricular dysfunction.
  7. Cardiac amyloidosis
  8. Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or right heart catheterization.
  9. Lower extremity venous thrombosis and/or the presence of an IVC filter at the time of or 6 months prior to TricValve procedure.
  10. Hemodynamically significant pericardial effusion.
  11. Patient with heart failure requiring advanced intervention (i.e. left ventricular assist device, transplantation) (ACC/ AHA/ ESC/ EACTS Stage D heart failure)
  12. Any known allergy or to nitinol, bovine tissue or contrast media that cannot be adequately treated with pre-medication.
  13. Unable to tolerate anticoagulation/antiplatelet therapy
  14. Hemodynamic instability, cardiogenic shock, inotropic support, intra-aortic balloon pump or acute heart failure within 30 days prior to the TricValve procedure.
  15. Any known life-threatening condition with an estimated life span of at least 12 months.
  16. count \< 75,000/mm3
  17. Severity Class C (10-15 points).
  18. Severe renal insufficiency with estimated (eGFR) ≤ 25 mL/min/1.73 m2 or requiring chronic renal replacement therapy at the time of enrollment.
  19. Endocarditis or active/ongoing infection requiring antibiotics.
  20. Unable to walk at least 60 meters in a 6minute walk test.
  21. Known bleeding or clotting disorders or patient refuses blood transfusion.
  22. Active gastrointestinal (GI) bleeding within 3 months of randomization.
  23. Presence of significant congenital heart disease including but not limited to hemodynamically significant atrial septal defect, RV dysplasia, and arrhythmogenic RV.
  24. Use or participation in other device or drug study in which patient has not reached a primary endpoint to treat cardiovascular conditions related to the outcomes of the current study.
  25. Any other condition that would preclude ability to meet study requirements in the opinion of the investigator.
  26. Psychiatric/behavioral issues or other medical or social conditions that preclude valid consent and follow-up
  27. Pregnant or breastfeeding subjects and those who plan pregnancy during the clinical investigation follow-up period.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    TricValve® Device (Device) Group

    subjects will undergo TricValve® implantation and will continue to be managed with optimal medical therapies, per physician discretion.

    Device: TricValve® Transcatheter Bicaval Valve System

Interventions

  • DeviceTricValve® Transcatheter Bicaval Valve System

    The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The system is a single use, sterile device compatible with all the valve sizes. The valves are premounted in the TricValve® Delivery System. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system available in sizes 25 and 29 for superior vena cava and 31 and 35 for inferior vena cava. The valve is implanted percutaneously by the transfemoral approach. The valves are supplied already premounted into the TricValve® Delivery System.

    Also known as: TricValve System

06

What researchers measure

Primary outcomes

  1. Mortality

    Number of days until death

    Time frame: 1 Month and 12 Months

  2. Stroke

    Number of days until death

    Time frame: 1 Month

  3. Pulmonary Embolism

    Number of days until death

    Time frame: 1 Month

  4. Valve Academic Research Consortium (VARC) type 2-4 bleeding complication

    Number of days until death

    Time frame: 1 Month

  5. Major vascular, access-related, or cardiac structural complication

    Number of days until death

    Time frame: 1 Month

  6. Stage 3 Acute Kidney Injury with increase in serum creatinine >300% (>3.0x increase) and/or serum creatinine ≥4.0mg/dL (≥354 μmol/L) with an acute increase of ≥ 0.5 mg/dL (≥44 μmol/L)

    Number of days from baseline until increase

    Time frame: 7 Days

  7. Stage 4 Acute Kidney Injury requiring new temporary or permanent renal replacement therapy

    Number of days until new renal replacement therapy

    Time frame: 1 Month

  8. Emergency surgery or intervention related to the device/procedure complications

    Number of days until emergency surgery or intervention

    Time frame: 1 Month

  9. Right Ventricular Assist Device (RVAD) implantation or heart transplant

    Number of days until Right Ventricular Assist Device (RVAD) implantation or heart transplant

    Time frame: 12 Months

  10. Tricuspid valve surgery or percutaneous tricuspid intervention

    Number of days until tricuspid valve surgery or percutaneous tricuspid intervention

    Time frame: 12 Months

  11. Heart Failure Events

    Number of heart failure episodes including hospitalization, or worsening heart failure

    Time frame: 12 Months

  12. Kansas City Cardiomyopathy Questionnaire (KCCQ) Score

    Change in KCC score (score ranges between 0 and 100)

    Time frame: 12 Months

  13. New York Heart Association (NYHA class)

    Change in NYHA class (range from I to IV)

    Time frame: 12 Months

  14. Six Minute Walking Test (6MWT)

    Change in walking distance

    Time frame: 12 Months

Secondary outcomes

  1. Technical success of device placement (at exit from procedure room)

    * Freedom from mortality * Successful access, delivery of the device, and retrieval of the delivery system * Correct positioning of the device into the proper anatomical location * Freedom from surgery or intervention related to the device or to a major vascular or access-related, or cardiac structural complication

    Time frame: Intraprocedural

  2. Device success within 30 days after device placement

    * Technical success * Freedom from mortality * Freedom from surgery or intervention related to the device or to a major vascular or access-related or cardiac structural complication

    Time frame: 1 Month

  3. Procedural success (at 30 days)

    All of the following criteria must be met to be considered a procedural success: * Device success (defined above), and * Absence of major device or procedure related serious adverse events

    Time frame: 1 Month

  4. Mortality

    Number of days until death

    Time frame: 12 Months

  5. RVAD implantation or heart transplant

    Number of days until Right Ventricular Assist Device (RVAD) implantation or heart transplant

    Time frame: 12 Months

  6. Tricuspid valve surgery or percutaneous tricuspid intervention

    Number of days until tricuspid valve surgery or percutaneous tricuspid intervention

    Time frame: 12 Months

  7. Heart Failure hospitalization or worsening Heart Failure (HF) which encompasses treatment with IV diuretics in the office or Emergency Department treatment during a <24-hour time period

    Number of days until Heart Failure hospitalization or worsening Heart Failure

    Time frame: 12 Months

  8. Kansas City Cardiomyopathy Questionnaire (KCCQ) Score

    Change in KCCQ score (score ranges between 0 and 100)

    Time frame: 12 Months

  9. New York Heart Association (NYHA class)

    Change in NYHA class (range from I to IV)

    Time frame: 12 Months

  10. Six Minute Walking Test (6MWT)

    Change in walking distance

    Time frame: 12 Months

07

Study locations

36 sites
08

References and documents

Publications

  • Estevez-Loureiro R, Sanchez-Recalde A, Amat-Santos IJ, Cruz-Gonzalez I, Baz JA, Pascual I, Mascherbauer J, Abdul-Jawad Altisent O, Nombela-Franco L, Pan M, Trillo R, Moreno R, Delle Karth G, Salido-Tahoces L, Santos-Martinez S, Nunez JC, Moris C, Goliasch G, Jimenez-Quevedo P, Ojeda S, Cid-Alvarez B, Santiago-Vacas E, Jimenez-Valero S, Serrador A, Martin-Moreiras J, Strouhal A, Hengstenberg C, Zamorano JL, Puri R, Iniguez-Romo A. 6-Month Outcomes of the TricValve System in Patients With Tricuspid Regurgitation: The TRICUS EURO Study. JACC Cardiovasc Interv. 2022 Jul 11;15(13):1366-1377. doi: 10.1016/j.jcin.2022.05.022. Epub 2022 May 17. PubMed 35583363 ↗
  • Amat-Santos IJ, Estevez-Loureiro R, Sanchez-Recalde A, Cruz-Gonzalez I, Pascual I, Mascherbauer J, Abdul-Jawad Altisent O, Nombela-Franco L, Pan M, Trillo R, Moreno R, Delle Karth G, Blasco-Turrion S, Sanchez-Luna JP, Revilla-Orodoea A, Redondo A, Zamorano JL, Puri R, Iniguez-Romo A, San Roman A. Right heart remodelling after bicaval TricValve implantation in patients with severe tricuspid regurgitation. EuroIntervention. 2023 Aug 7;19(5):e450-e452. doi: 10.4244/EIJ-D-23-00077. No abstract available. PubMed 37083622 ↗
  • Abdul-Jawad Altisent O, Codina P, Puri R, Bayes-Genis A. Transcatheter bi-caval valve implantation (CAVI) significantly improves cardiac output: mechanistic insights following CardioMEMS(R) and TricValve(R) implantation. Clin Res Cardiol. 2022 Aug;111(8):966-968. doi: 10.1007/s00392-022-02029-8. Epub 2022 May 2. No abstract available. PubMed 35499708 ↗
  • Chandran K, Long A, Bishop J, Berman P, Matar F, Oliveira GH, Bezerra HG. First In-Man Experience With TricValve Transcatheter Bicaval Valve System in Left Ventricular Assist Device Heartmate II Patient for High-Risk Tricuspid Regurgitation. Circ Heart Fail. 2023 Jun;16(6):e010027. doi: 10.1161/CIRCHEARTFAILURE.122.010027. Epub 2023 Jun 6. No abstract available. PubMed 37278243 ↗

Individual participant data

Plan to share: Yes — The dataset generated during and/or analysed during the study will be available upon request from the Clinical Research Organization, Meditrial USA Inc. m.tocchi@meditrial.net Datasets will only be made available through publication, unless disclosure is mandated by law.

Access criteria: Available on request, Published as a supplement to the results publication.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Sep 2026, 26 months after the start.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 26 months is below that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 18, 2023
StartActual
Jul 23, 2024
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2029
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06137807
Lead sponsor
P+F Products + Features USA Inc.
Collaborators
P+F Products + Features GmbH, Meditrial USA Inc.
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Jul 23, 2024
Primary completion
Sep 2026 (estimated)
Completion
Sep 2029 (estimated)
Last update
Aug 28, 2026

Study contacts

Katharina Kiss, MD
study chair · Products & Features GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion